← Leaderboards
Anette Schneemann
Scripps Research Institute
$7,127,375
Attributed
$7,388,488
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $816K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$7,388,488 · 6
By mechanism
R01$4,883,487 · 1
R21$2,085,601 · 4
R56$419,400 · 1
Top collaborators
- Marianne Manchester2 shared
Most similar at Scripps Research Institute
Same institution · by research overlap
- Juan C. De La Torre$34,810,527
- Paul R Schimmel$17,560,948
- Shankar Subramaniam$69,706,556
- Joel M. Gottesfeld$21,130,203
- John Johnson$22,284,193
Others in their field
Top investigators on “Virion”
- Dennis R. Burton · Scripps Research Institute$211,129,427
- Alice Telesnitsky · University Of Michigan At Ann Arbor$28,932,043
- Joseph G Sodroski · University Of Pennsylvania$25,257,338
- Richard J. Kuhn · Purdue University$24,871,738
- Michael R. Farzan · Boston Children'S Hospital$23,528,325
- Kevin O Saunders · Duke University$22,603,553
Research focus
VirionVirusHousingParticleInsect VirusesVirus AssemblyBinding (Molecular Function)DesignViralBasePublic Health RelevanceIn VivoAntibodiesVaccinesSurfaceVaccine DevelopmentVirus-Like ParticleResearch StudyImmune ResponseInfectionMolecularCryoelectron MicroscopyProteinsGenome
Grant awards (21)
Development of a structure-based HCV vaccine using a virus-like particle platform$284,250
R21 · FY2015 · AI · contact PI
Developing a structure-specific HIV vaccine using chimeric virus-like particles$284,250
R21 · FY2014 · AI · contact PI
Development of a structure-based HCV vaccine using a virus-like particle platform$236,875
R21 · FY2014 · AI · contact PI
Virus-host interactions during nodaviral infection$419,181
R01 · FY2013 · GM · contact PI
Developing a structure-specific HIV vaccine using chimeric virus-like particles$236,875
R21 · FY2013 · AI · contact PI
Virus-host interactions during nodaviral infection$434,384
R01 · FY2012 · GM · contact PI
Development of a broadly neutralizing influenza virus vaccine$284,250
R21 · FY2012 · AI · contact PI
Virus-host interactions during nodaviral infection$434,384
R01 · FY2011 · GM · contact PI
Development of a broadly neutralizing influenza virus vaccine$236,875
R21 · FY2011 · AI · contact PI
Virus-host interactions during nodaviral infection$438,772
R01 · FY2010 · GM · contact PI
Multivalent VAccines for Biodefense$261,113
R21 · FY2010 · AI · contact PI
Multivalent VAccines for Biodefense$261,113
R21 · FY2009 · AI · contact PI
Molecular determinants of nodaviral assembly$404,281
R01 · FY2008 · GM · contact PI
Molecular analysis of nodaviral suppression of RNA interference$419,400
R56 · FY2007 · AI · contact PI
Molecular determinants of nodaviral assembly$396,601
R01 · FY2007 · GM · contact PI
Molecular determinants of nodaviral assembly$408,446
R01 · FY2006 · GM · contact PI
Molecular determinants of nodaviral assembly$444,993
R01 · FY2005 · GM
ROLE OF NUCLEIC ACID IN RNA VIRUSES$379,660
R01 · FY2004 · GM
ROLE OF NUCLEIC ACID IN RNA VIRUSES$379,660
R01 · FY2003 · GM
ROLE OF NUCLEIC ACID IN RNA VIRUSES$379,660
R01 · FY2002 · GM
ROLE OF NUCLEIC ACID IN RNA VIRUSES$363,465
R01 · FY2001 · GM